Evommune (EVMN) has just wrapped up FY 2025 with Q4 revenue at US$0 million, a basic EPS loss of US$1.43 per share, and trailing twelve month revenue of US$13 million against a net loss of US$68.87 million. Over recent periods, the company has seen quarterly revenue move between US$0 million and US$10 million while quarterly EPS losses ranged from about US$1.43 to US$14.54 per share. This sets a clear picture of a business still investing heavily ahead of potential payoffs. For investors, the key question this season is whether that revenue base can eventually support the current loss profile and move the company toward healthier margins.

See our full analysis for Evommune.

With the headline numbers on the table, the next step is to see how these results line up with the most widely shared narratives around Evommune, and where the data starts to push back on those stories.

Revenue Growth Meets Heavy Losses

• Over the last year, revenue of US$13 million sits against a trailing twelve month net loss of US$68.87 million, so every dollar of revenue is currently paired with several dollars of loss.
• What stands out for a bullish view that focuses on the 85.7% revenue growth and the forecast 53.4% annual growth is that those same forecasts also show earnings expected to decline by about 18.6% per year. This means:
  • The strong top line in FY 2025, including quarters like Q3 with US$10 million in revenue, has not yet translated into improving earnings, as the latest trailing twelve month net loss is still US$68.87 million.
  • Bulls who lean on the revenue ramp need to factor in that the company is currently unprofitable and is not forecast to reach profitability over the next three years, so the gap between growth and losses remains a key issue.

Quarterly Swings In Revenue And EPS

• Within FY 2025, revenue moved from US$3 million in Q1 to US$0 in Q2, then up to US$10 million in Q3 before dropping back to US$0 in Q4, while basic EPS losses ranged from about US$1.43 per share in Q4 to US$9.48 per share in Q1.
• Critics who take a more bearish stance on earnings consistency could point to these swings as a sign that the loss profile is still heavy, as seen in quarterly net losses between US$12.48 million and US$28.27 million in FY 2025, but:
  • The trailing twelve month basic EPS loss improved from US$52.53 per share at the start of FY 2025 to US$11.22 per share by Q4, which may soften the bearish argument that losses are only getting worse.
  • At the same time, the trailing twelve month net loss of US$68.87 million is close to the US$68.31 million loss a year earlier, so anyone worried about earnings durability can point to a sizeable loss level that has not yet moved closer to break even.

Valuation And Volatility Pull In Opposite Directions

• On the valuation side, the stock trades on a P/B of 3.9x, below a 7.1x peer average but above the broader US Biotechs industry at 2.5x, while the share price of US$22.50 sits below the analyst median target of US$51.88 that implies about 130.6% upside.
• For investors weighing a more bullish narrative against the risk profile, the mix of high revenue growth, expected multi year earnings declines of around 18.6% per year and recent share price volatility creates a clear tension, because:
  • Supporters can point to the combination of strong trailing revenue growth of 85.7% and analyst target upside versus the current US$22.50 share price as signals that the growth story is being recognized.
  • More cautious investors can focus on the high volatility over the last three months and the fact that the company remains unprofitable on a trailing twelve month basis, which makes any valuation based on P/B or price targets highly sensitive to changes in sentiment.

For a fuller picture of how these earnings tie into longer term growth, risks and valuation, you can see what other investors are saying in the Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Evommune's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Given the mix of concerns and optimism running through these results, it makes sense to look at the numbers yourself and move quickly in forming your own stance. Start with a close look at the 3 key rewards and 3 important warning signs.

See What Else Is Out There

Evommune combines a heavy net loss of US$68.87 million with volatile quarterly revenue and a lack of expected profitability over the next three years.

If that level of uncertainty feels uncomfortable, shift some research time toward companies screened as 72 resilient stocks with low risk scores to focus on steadier business and risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.